Literature DB >> 1696002

Detection of point mutations in type I collagen by RNase digestion of RNA/RNA hybrids.

D K Grange1, G S Gottesman, M B Lewis, J C Marini.   

Abstract

We have developed a strategy for the detection, localization and sequence determination of point mutations in the mRNA coding for the alpha 1(I) and alpha 2(I) chains of type I collagen. Point mutations are detected by RNase A cleavage of mismatches in RNA/RNA hybrids. The mRNAs coding for the fibrillar collagens present special problems for hybrid analysis because of their large size and their GC-rich and repetitive sequences. We have generated a series of overlapping antisense riboprobes covering the entire pro alpha 1(I) and pro alpha 2(I) mRNAs. Uniformly labelled normal antisense riboprobes are hybridized with the total fibroblast RNA of patients with possible mutations in type I collagen. Mismatches in the resulting RNA/RNA hybrids are cleaved with RNase A and the labelled riboprobe cleavage products are examined electrophoretically. The sensitivity and specificity of the system were demonstrated by the detection and localization of a known point mutation in the codon for alpha 1(I) glycine 988 (1). DNA for sequencing the mutations localized by hybrid analysis may be obtained by either (1) generation of a fibroblast cDNA library and isolation of both alleles by plaque screening, or (2) a more rapid method using first strand cDNA synthesis from poly (A+)-mRNA, followed by PCR amplification of the mutation-containing region of the DNA/RNA hybrid. This strategy for detection and isolation has wide application not only for mutations causing connective tissue disorders, but also for mutations in other large and repetitive genes. We have used this strategy for the detection and sequencing of a point mutation in alpha 2(I) mRNA associated with a case of lethal osteogenesis imperfecta. The G----A point mutation in the codon for alpha 2(I) glycine residue 805 results in the substitution of an aspartic acid at this position and is consistent with the proband's collagen protein data.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696002      PMCID: PMC331183          DOI: 10.1093/nar/18.14.4227

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  27 in total

1.  Organization of the human pro-alpha 2(I) collagen gene.

Authors:  W de Wet; M Bernard; V Benson-Chanda; M L Chu; L Dickson; D Weil; F Ramirez
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

2.  Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta.

Authors:  J Bonadio; K A Holbrook; R E Gelinas; J Jacob; P H Byers
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

3.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

4.  Lethal osteogenesis imperfecta resulting from a single nucleotide change in one human pro alpha 1(I) collagen allele.

Authors:  D H Cohn; P H Byers; B Steinmann; R E Gelinas
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

6.  A point mutation in a type I procollagen gene converts glycine 748 of the alpha 1 chain to cysteine and destabilizes the triple helix in a lethal variant of osteogenesis imperfecta.

Authors:  B E Vogel; R R Minor; M Freund; D J Prockop
Journal:  J Biol Chem       Date:  1987-10-25       Impact factor: 5.157

7.  Substitution of arginine for glycine 664 in the collagen alpha 1(I) chain in lethal perinatal osteogenesis imperfecta. Demonstration of the peptide defect by in vitro expression of the mutant cDNA.

Authors:  J F Bateman; S R Lamande; H H Dahl; D Chan; W G Cole
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

8.  A lethal variant of osteogenesis imperfecta has a single base mutation that substitutes cysteine for glycine 904 of the alpha 1(I) chain of type I procollagen. The asymptomatic mother has an unidentified mutation producing an overmodified and unstable type I procollagen.

Authors:  C D Constantinou; K B Nielsen; D J Prockop
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

9.  Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes.

Authors:  R M Myers; Z Larin; T Maniatis
Journal:  Science       Date:  1985-12-13       Impact factor: 47.728

10.  Cloning a cDNA for the pro-alpha 2 chain of human type I collagen.

Authors:  J C Myers; M L Chu; S H Faro; W J Clark; D J Prockop; F Ramirez
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

View more
  4 in total

1.  Second-site suppressor mutations assist in studying the function of the 3' noncoding region of turnip yellow mosaic virus RNA.

Authors:  C H Tsai; T W Dreher
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Biochemical screening of type I collagen in osteogenesis imperfecta: detection of glycine substitutions in the amino end of the alpha chains requires supplementation by molecular analysis.

Authors:  W A Cabral; S Milgrom; A D Letocha; E Moriarty; J C Marini
Journal:  J Med Genet       Date:  2006-08       Impact factor: 6.318

3.  Experimental evaluation of the ribonuclease protection assay method for the assessment of genetic heterogeneity in populations of RNA viruses.

Authors:  M A Aranda; A Fraile; F Garcia-Arenal; J M Malpica
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders.

Authors:  Q Wang; J C Marini
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.